<p>CG Oncology, Inc.（纳斯达克代码：CGON - 获取免费报告）在周一市场开盘前股价跳涨，此前一位内部人士购买了该公司的额外股份。该股此前收于 33.34 美元，但开盘时为 35.10 美元。CG Oncology 的股票最后交易价格为 34.33 美元，成交量为 114,584 股。</p>
<ul>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
</ul>
<p>具体来说，董事 Brian Guan-Chyun Liu 在 9 月 11 日（星期四）进行了一笔交易，购买了 1,515,151 股该公司的股票。这些股票的平均购买价格为每股 33.00 美元，总价值为 49,999,983.00 美元。购买后，该董事持有 1,515,151 股公司的股票，价值 49,999,983 美元。这笔交易代表了他们对该股票持有量的∞增长。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。</p>
<h2>华尔街分析师观点</h2>
<p>几家研究公司对 CGON 发表了看法。加拿大皇家银行在 7 月 16 日的报告中将 CG Oncology 的目标价从 68.00 美元下调至 53.00 美元，并给予该公司 “跑赢大盘” 的评级。Piper Sandler 在 8 月 18 日的报告中开始覆盖 CG Oncology，给予 “增持” 评级，并设定 55.00 美元的目标价。Wall Street Zen 在 8 月 9 日的报告中将 CG Oncology 的评级从 “持有” 下调至 “卖出”。Zacks Research 在 9 月 1 日的报告中将 CG Oncology 的评级从 “强烈卖出” 上调至 “持有”。最后，摩根士丹利在 7 月 10 日的报告中将 CG Oncology 的评级上调至 “强烈买入”，并设定 40.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，十位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 53.91 美元。</p>
<p><strong>查看我们关于 CG Oncology 的最新报告</strong></p>
<h2>CG Oncology 股价上涨 2.3%</h2>
<p>该股市值为 26 亿美元，市盈率为-19.26，贝塔值为 0.87。该公司的 50 日简单移动平均线为 27.20 美元，200 日简单移动平均线为 25.55 美元。</p>
<p>CG Oncology（纳斯达克代码：CGON - 获取免费报告）最近一次发布财报是在 8 月 8 日（星期五）。该公司报告每股收益（EPS）为-0.54 美元，低于分析师一致预期的-0.49 美元，差距为 0.05 美元。CG Oncology 的净利润率为-15,945.17%，股本回报率为-19.37%。整体来看，研究分析师预计 CG Oncology, Inc.在本年度的每股收益将为-1.31 美元。</p>
<h2>机构投资者对 CG Oncology 的看法</h2>
<p>机构投资者最近调整了对该股票的持有情况。GF Fund Management CO. LTD.在第四季度收购了 CG Oncology 的新股份，价值 41,000 美元。Winthrop Capital Management LLC 在第二季度购买了 CG Oncology 的新头寸，价值 38,000 美元。CWM LLC 在第一季度将其在 CG Oncology 的持股增加了 3,957.7%。CWM LLC 目前持有 2,110 股该公司的股票，价值 52,000 美元，此前在该期间内又购买了 2,058 股。GAMMA Investing LLC 在第一季度将其在 CG Oncology 的持股增加了 1,051.0%。GAMMA Investing LLC 目前持有 2,302 股该公司的股票，价值 56,000 美元，此前在该期间内又购买了 2,102 股。最后，未来资产全球投资有限公司在第二季度将其在 CG Oncology 的持股增加了 15.6%。未来资产全球投资有限公司目前持有 2,945 股该公司的股票，价值 77,000 美元，此前在该期间内又购买了 398 股。机构投资者和对冲基金持有该公司 26.56% 的股份。</p>
<h2>关于 CG Oncology</h2>
<p>（获取免费报告）</p>
<p>CG Oncology, Inc.是一家专注于开发和商业化基础膀胱保留治疗的肿瘤免疫治疗公司，旨在为膀胱癌患者提供治疗。该公司开发 BOND-003 用于治疗高风险的卡介苗（BCG）无反应非肌肉侵袭性膀胱癌（NMIBC）患者；CORE-001 用于治疗与 pembrolizumab 联合使用的 cretostimogene，针对高风险 BCG 无反应的 NMIBC 患者；以及 CORE-002 用于治疗与检查点抑制剂 nivolumab 联合使用的 cretostimogene，针对肌肉侵袭性膀胱癌患者。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 CG Oncology</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>应用数字突破仅仅是开始</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>三只图表看涨且有充足上行空间的热门科技股</li>
<li>动量投资与长期投资的区别</li>
<li>生物科技行业可能在年底前转变为市场领头羊</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CG Oncology 吗？</h2>
<p>在考虑 CG Oncology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 CG Oncology 并不在名单上。</p>
<p>虽然 CG Oncology 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGON

<p>CG Oncology（纳斯达克代码：CGON）股价在内部人士购股后大幅上涨，开盘价为 35.10 美元，较前一交易日收盘价 33.34 美元上涨。董事 Brian Liu 以每股 33.00 美元的价格购买了 150 万股，总计近 5000 万美元。分析师对该股的评级不一，目标价范围在 40 美元到 68 美元之间。该公司的市值为 26 亿美元，市盈率为-19.26。机构投资者持有 26.56% 的股份。CG Oncology 专注于膀胱癌疗法，上个季度报告每股亏损 0.54 美元，未能达到预期</p>

<p>CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) shares gapped up before the market opened on Monday after an insider bought additional shares in the company. The stock had previously closed at $33.34, but opened at $35.10. CG Oncology shares last traded at $34.33, with a volume of 114,584 shares.</p>
<div class="lb-trans"><p>CG Oncology, Inc.（纳斯达克代码：CGON - 获取免费报告）在周一市场开盘前股价跳涨，此前一位内部人士购买了该公司的额外股份。该股此前收于 33.34 美元，但开盘时为 35.10 美元。CG Oncology 的股票最后交易价格为 34.33 美元，成交量为 114,584 股。</p>
</div><ul>
<li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>发现 2024 年表现最佳的三只生物科技 IPO 股票</li>
</ul>
</div><p>Specifically, Director Brian Guan-Chyun Liu bought 1,515,151 shares of the firm's stock in a transaction that occurred on Thursday, September 11th. The shares were bought at an average price of $33.00 per share, with a total value of $49,999,983.00. Following the purchase, the director owned 1,515,151 shares of the company's stock, valued at $49,999,983. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.</p>
<div class="lb-trans"><p>具体来说，董事 Brian Guan-Chyun Liu 在 9 月 11 日（星期四）进行了一笔交易，购买了 1,515,151 股该公司的股票。这些股票的平均购买价格为每股 33.00 美元，总价值为 49,999,983.00 美元。购买后，该董事持有 1,515,151 股公司的股票，价值 49,999,983 美元。这笔交易代表了他们对该股票持有量的∞增长。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research firms have weighed in on CGON. Royal Bank Of Canada cut their price target on CG Oncology from $68.00 to $53.00 and set an &#34;outperform&#34; rating for the company in a report on Wednesday, July 16th. Piper Sandler began coverage on CG Oncology in a report on Monday, August 18th. They set an &#34;overweight&#34; rating and a $55.00 price target for the company. Wall Street Zen cut CG Oncology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, August 9th. Zacks Research upgraded CG Oncology from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, September 1st. Finally, The Goldman Sachs Group upgraded CG Oncology to a &#34;strong-buy&#34; rating and set a $40.00 price target for the company in a report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $53.91.</p>
<div class="lb-trans"><p>几家研究公司对 CGON 发表了看法。加拿大皇家银行在 7 月 16 日的报告中将 CG Oncology 的目标价从 68.00 美元下调至 53.00 美元，并给予该公司 “跑赢大盘” 的评级。Piper Sandler 在 8 月 18 日的报告中开始覆盖 CG Oncology，给予 “增持” 评级，并设定 55.00 美元的目标价。Wall Street Zen 在 8 月 9 日的报告中将 CG Oncology 的评级从 “持有” 下调至 “卖出”。Zacks Research 在 9 月 1 日的报告中将 CG Oncology 的评级从 “强烈卖出” 上调至 “持有”。最后，摩根士丹利在 7 月 10 日的报告中将 CG Oncology 的评级上调至 “强烈买入”，并设定 40.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，十位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 53.91 美元。</p>
</div><p><strong>Check Out Our Latest Report on CG Oncology</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CG Oncology 的最新报告</strong></p>
</div><h2>CG Oncology Trading Up 2.3%</h2>
<div class="lb-trans"><h2>CG Oncology 股价上涨 2.3%</h2>
</div><p>The stock has a market capitalization of $2.60 billion, a PE ratio of -19.26 and a beta of 0.87. The firm's 50-day simple moving average is $27.20 and its two-hundred day simple moving average is $25.55.</p>
<div class="lb-trans"><p>该股市值为 26 亿美元，市盈率为-19.26，贝塔值为 0.87。该公司的 50 日简单移动平均线为 27.20 美元，200 日简单移动平均线为 25.55 美元。</p>
</div><p>CG Oncology (NASDAQ:CGON - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. As a group, research analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.</p>
<div class="lb-trans"><p>CG Oncology（纳斯达克代码：CGON - 获取免费报告）最近一次发布财报是在 8 月 8 日（星期五）。该公司报告每股收益（EPS）为-0.54 美元，低于分析师一致预期的-0.49 美元，差距为 0.05 美元。CG Oncology 的净利润率为-15,945.17%，股本回报率为-19.37%。整体来看，研究分析师预计 CG Oncology, Inc.在本年度的每股收益将为-1.31 美元。</p>
</div><h2>Institutional Investors Weigh In On CG Oncology</h2>
<div class="lb-trans"><h2>机构投资者对 CG Oncology 的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. acquired a new stake in shares of CG Oncology during the 4th quarter valued at $41,000. Winthrop Capital Management LLC bought a new position in CG Oncology in the 2nd quarter worth $38,000. CWM LLC increased its holdings in shares of CG Oncology by 3,957.7% during the 1st quarter. CWM LLC now owns 2,110 shares of the company's stock worth $52,000 after purchasing an additional 2,058 shares during the period. GAMMA Investing LLC increased its holdings in shares of CG Oncology by 1,051.0% during the 1st quarter. GAMMA Investing LLC now owns 2,302 shares of the company's stock worth $56,000 after purchasing an additional 2,102 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of CG Oncology by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company's stock worth $77,000 after purchasing an additional 398 shares during the period. Institutional investors and hedge funds own 26.56% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有情况。GF Fund Management CO. LTD.在第四季度收购了 CG Oncology 的新股份，价值 41,000 美元。Winthrop Capital Management LLC 在第二季度购买了 CG Oncology 的新头寸，价值 38,000 美元。CWM LLC 在第一季度将其在 CG Oncology 的持股增加了 3,957.7%。CWM LLC 目前持有 2,110 股该公司的股票，价值 52,000 美元，此前在该期间内又购买了 2,058 股。GAMMA Investing LLC 在第一季度将其在 CG Oncology 的持股增加了 1,051.0%。GAMMA Investing LLC 目前持有 2,302 股该公司的股票，价值 56,000 美元，此前在该期间内又购买了 2,102 股。最后，未来资产全球投资有限公司在第二季度将其在 CG Oncology 的持股增加了 15.6%。未来资产全球投资有限公司目前持有 2,945 股该公司的股票，价值 77,000 美元，此前在该期间内又购买了 398 股。机构投资者和对冲基金持有该公司 26.56% 的股份。</p>
</div><h2>About CG Oncology</h2>
<div class="lb-trans"><h2>关于 CG Oncology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.</p>
<div class="lb-trans"><p>CG Oncology, Inc.是一家专注于开发和商业化基础膀胱保留治疗的肿瘤免疫治疗公司，旨在为膀胱癌患者提供治疗。该公司开发 BOND-003 用于治疗高风险的卡介苗（BCG）无反应非肌肉侵袭性膀胱癌（NMIBC）患者；CORE-001 用于治疗与 pembrolizumab 联合使用的 cretostimogene，针对高风险 BCG 无反应的 NMIBC 患者；以及 CORE-002 用于治疗与检查点抑制剂 nivolumab 联合使用的 cretostimogene，针对肌肉侵袭性膀胱癌患者。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than CG Oncology</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>The Applied Digital Breakout Is Only the Beginning</li>
<li>What is the S&amp;P/TSX Index?</li>
<li>3 Hot Tech Stocks With Bullish Charts and Ample Upside</li>
<li>Differences Between Momentum Investing and Long Term Investing</li>
<li>Biotech Sector May Flip to Market Leader by Year-End</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 CG Oncology</li>
<li>高飞者：2022 年 3 月的三只天然气股票</li>
<li>应用数字突破仅仅是开始</li>
<li>S&amp;P/TSX 指数是什么？</li>
<li>三只图表看涨且有充足上行空间的热门科技股</li>
<li>动量投资与长期投资的区别</li>
<li>生物科技行业可能在年底前转变为市场领头羊</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CG Oncology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CG Oncology 吗？</h2>
</div><p>Before you consider CG Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CG Oncology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 CG Oncology 并不在名单上。</p>
</div><p>While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CG Oncology 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

CG Oncology（纳斯达克代码：CGON）股票在内部人士买入活动后出现跳空高开